| General Information | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000040422240 |
| Molecular Weight (Da) | 438 |
| SMILES | CCOc1ccc([C@@H](O)c2nc3cc(C(=O)N(CC)CC)ccc3n2CCC(C)C)cc1 |
| Molecular Formula | C26N3O3 |
| Action | Agonist |
| General Information | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000040422240 |
| Molecular Weight (Da) | 438 |
| SMILES | CCOc1ccc([C@@H](O)c2nc3cc(C(=O)N(CC)CC)ccc3n2CCC(C)C)cc1 |
| Molecular Formula | C26N3O3 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000040422240 |
| Molar Refractivity | 126.76 |
| HBA | 4 |
| HBD | 1 |
| Rotatable Bonds | 10 |
| Heavy Atoms | 32 |
| LogP | 4.838 |
| Activity (Ki) in nM | 57.544 |
| Polar Surface Area (PSA) | 67.59 |
| Pharmacokinetic Properties | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000040422240 |
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Oatp2b1 inhibitor | - |
| Oatp1b1 inhibitor | + |
| Oatp1b3 inhibitor | + |
| Mate1 inhibitor | - |
| Oct2 inhibitor | - |
| Bsep inhibitor | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.9910472 |
| Pharmacokinetic Properties | |
|---|---|
| Number of aromatic heavy atoms | 15 |
| Fraction csp3 | 0.46 |
| Ilogp | 4.26 |
| Xlogp3 | 4.44 |
| Wlogp | 4.72 |
| Mlogp | 3.02 |
| Silicos-it log p | 4.81 |
| Consensus log p | 4.25 |
| Esol log s | -4.97 |
| Esol solubility (mg/ml) | 4.68E-03 |
| Esol solubility (mol/l) | 1.07E-05 |
| Esol class | Moderately |
| Ali log s | -5.58 |
| Ali solubility (mg/ml) | 1.16E-03 |
| Ali solubility (mol/l) | 2.64E-06 |
| Ali class | Moderately |
| Silicos-it logsw | -7 |
| Silicos-it solubility (mg/ml) | 4.40E-05 |
| Silicos-it solubility (mol/l) | 1.00E-07 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.82 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 1 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 3.8 |
| Pharmacokinetic Properties | |
|---|---|
| Logs | -4.645 |
| Logd | 3.67 |
| Logp | 4.268 |
| F (20%) | 0.005 |
| F (30%) | 0.842 |
| Mdck | 1.16E-05 |
| Ppb | 0.9236 |
| Vdss | 1.089 |
| Fu | 0.0473 |
| Cyp1a2-inh | 0.137 |
| Cyp1a2-sub | 0.494 |
| Cyp2c19-inh | 0.886 |
| Cyp2c19-sub | 0.238 |
| Cl | 4.204 |
| T12 | 0.21 |
| H-ht | 0.178 |
| Dili | 0.777 |
| Roa | 0.019 |
| Fdamdd | 0.877 |
| Skinsen | 0.032 |
| Ec | 0.003 |
| Ei | 0.011 |
| Respiratory | 0.696 |
| Bcf | 1.999 |
| Igc50 | 4.563 |
| Lc50 | 5.731 |
| Lc50dm | 5.686 |
| Nr-ar | 0.156 |
| Nr-ar-lbd | 0.005 |
| Nr-ahr | 0.635 |
| Nr-aromatase | 0.757 |
| Nr-er | 0.433 |
| Nr-er-lbd | 0.314 |
| Nr-ppar-gamma | 0.008 |
| Sr-are | 0.198 |
| Sr-atad5 | 0.008 |
| Sr-hse | 0.033 |
| Sr-mmp | 0.544 |
| Sr-p53 | 0.578 |
| Vol | 470.852 |
| Dense | 0.929 |
| Flex | 17 |
| Nstereo | 0.647 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | 1 |
| Toxicophores | 0 |
| Qed | 2 |
| Synth | 0.482 |
| Fsp3 | 2.825 |
| Mce-18 | 0.462 |
| Natural product-likeness | 40 |
| Alarm nmr | -1.38 |
| Bms | 1 |
| Chelating | 0 |
| Pfizer | 1 |
| Gsk | Rejected |
| Goldentriangle | Rejected |